The US Patent and Trademark Office has once again decided that the institute has priority over the University of California and collaborators regarding intellectual property rights for CRISPR-Cas9 gene editing in eukaryotes. But the fight over the technique isn’t over.

In a win for the US Department of Justice’s China Initiative, Charles Lieber was convicted of hiding his financial ties to China from federal agencies.

The move, which is not supported by the pharmaceutical industry, would allow other countries to design and manufacture COVID-19 vaccines without fear of litigation.

Four Chinese nationals have been charged with visa fraud after revelations that they sent information on the layout of US labs and research carried out by colleagues back to China.

Administration officials and lawmakers say the move is to shore up national security threats, but university professors argue such cancellations represent targeted discrimination.

We present an economic plan for a collective sharing of scientific knowledge on the pandemic.

Prosecutors say two other researchers from the same cancer lab at Beth Israel Deaconess Medical Center successfully stole material and brought it to China.

The National Defense Authorization Act calls for a new task force and roundtable to limit foreign government involvement in federally funded research.

Hundreds of CRISPR patents have been granted around the world, and the number of applications continues to grow at a rapid pace.

The US patent office declares an interference between the intellectual property held by the Broad Institute and several patent applications filed by the University of California—opposite its previous ruling.

Changing policy has left academics uncertain about what is legal for foreign involvement in research, and increased hostility and bureaucracy have led students and scholars to seek opportunities elsewhere.

Scientists argue that anti-Chinese political rhetoric and policies could harm US research.

The higher court’s decision to uphold the ruling of the Patent Trial and Appeal Board essentially ends the intellectual property battle in the US.

The proposed limitations stem from fears of intellectual property theft.

In efforts to translate basic-science results into pharmaceuticals and other technologies, success cannot be taken for granted.

The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.

The University of California files a brief in its appeal challenging the ruling that the Broad Institute’s group would retain its CRISPR genome-editing patent.

The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.